ATE370139T1 - Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs - Google Patents
Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebsInfo
- Publication number
- ATE370139T1 ATE370139T1 AT03749105T AT03749105T ATE370139T1 AT E370139 T1 ATE370139 T1 AT E370139T1 AT 03749105 T AT03749105 T AT 03749105T AT 03749105 T AT03749105 T AT 03749105T AT E370139 T1 ATE370139 T1 AT E370139T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- treatment
- tgf beta
- beta inhibitors
- pyrazolopyridine derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- -1 pyrazolopyridine derivative compounds Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41156002P | 2002-09-17 | 2002-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370139T1 true ATE370139T1 (de) | 2007-09-15 |
Family
ID=32030690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03749105T ATE370139T1 (de) | 2002-09-17 | 2003-09-16 | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7365066B2 (de) |
| EP (1) | EP1543001B1 (de) |
| AT (1) | ATE370139T1 (de) |
| AU (1) | AU2003268156A1 (de) |
| DE (1) | DE60315677T2 (de) |
| ES (1) | ES2291664T3 (de) |
| WO (1) | WO2004026871A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| PL2918288T3 (pl) | 2006-10-03 | 2018-02-28 | Genzyme Corporation | Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej |
| EP2320737B1 (de) | 2008-08-05 | 2013-07-17 | Merck Sharp & Dohme Corp. | Pyrazolo-[1,5-a]-pyridine als mark-hemmer |
| FR2950345B1 (fr) * | 2009-09-18 | 2011-09-23 | Sanofi Aventis | Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique |
| ES2574253T3 (es) | 2009-12-18 | 2016-06-16 | Mitsubishi Tanabe Pharma Corporation | Nuevo agente antiplaquetario |
| EP2402337A1 (de) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridin-Verbindungen |
| EP2402335A1 (de) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridin-Verbindungen |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
| CA2853484C (en) | 2011-10-26 | 2018-08-21 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| EP3685855B1 (de) | 2012-10-05 | 2023-11-22 | Kadmon Corporation, LLC | Menschliche anti-vegfr-2-/kdr-antikörper |
| WO2014078802A1 (en) | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| WO2014159356A1 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion and culture |
| GB201321733D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SI3102576T1 (sl) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals, Llc | Inhibitorji dihidropirolopiridina ROR-gama |
| IL299964A (en) | 2014-09-03 | 2023-03-01 | Massachusetts Inst Technology | Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US10822337B2 (en) | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| WO2017087608A1 (en) | 2015-11-20 | 2017-05-26 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| JP2019506153A (ja) | 2016-01-08 | 2019-03-07 | マサチューセッツ インスティテュート オブ テクノロジー | 分化した腸内分泌細胞およびインスリン産生細胞の作製 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| CN110392686A (zh) | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| KR20200053481A (ko) | 2017-07-24 | 2020-05-18 | 비타이 파마슈티컬즈, 엘엘씨 | RORγ의 억제제 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
| JP7401435B2 (ja) * | 2017-12-13 | 2023-12-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | カルボキシエステラーゼ生体触媒 |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3827010B1 (de) | 2018-07-23 | 2025-08-27 | Brise Pharmaceuticals Co., Ltd. | Bisphosphonat-wirkstoff-konjugate |
| CA3109647A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| JP2022515652A (ja) | 2018-12-31 | 2022-02-21 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| CN113862710B (zh) * | 2021-09-17 | 2023-11-03 | 阜阳师范大学 | 一种二氢二吡唑[3,4-b:4′,3′-e]吡啶类化合物的电化学合成方法 |
| CN121712526A (zh) | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001139575A (ja) * | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
| JP2004521915A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ過剰発現に対するピラゾール誘導体 |
| GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| WO2002062787A1 (en) * | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| SK287857B6 (sk) * | 2001-05-24 | 2012-01-04 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
-
2003
- 2003-09-16 EP EP03749105A patent/EP1543001B1/de not_active Expired - Lifetime
- 2003-09-16 DE DE60315677T patent/DE60315677T2/de not_active Expired - Fee Related
- 2003-09-16 ES ES03749105T patent/ES2291664T3/es not_active Expired - Lifetime
- 2003-09-16 AU AU2003268156A patent/AU2003268156A1/en not_active Abandoned
- 2003-09-16 AT AT03749105T patent/ATE370139T1/de not_active IP Right Cessation
- 2003-09-16 WO PCT/US2003/026297 patent/WO2004026871A1/en not_active Ceased
- 2003-09-16 US US10/524,577 patent/US7365066B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7365066B2 (en) | 2008-04-29 |
| AU2003268156A1 (en) | 2004-04-08 |
| EP1543001B1 (de) | 2007-08-15 |
| ES2291664T3 (es) | 2008-03-01 |
| DE60315677D1 (de) | 2007-09-27 |
| US20050222197A1 (en) | 2005-10-06 |
| DE60315677T2 (de) | 2008-06-05 |
| EP1543001A1 (de) | 2005-06-22 |
| WO2004026871A1 (en) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE370139T1 (de) | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| HUS1600021I1 (hu) | MEK inhibitorok és módszerek azok felhasználására | |
| SE0301700D0 (sv) | Novel compounds | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200800555A1 (ru) | Производные ксантина в качестве селективных агонистов hm74a | |
| DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| EA200700188A1 (ru) | Производные замещенного 2-алкилхиназолинона как ингибиторы parp | |
| ATE438401T1 (de) | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen | |
| EA200501236A1 (ru) | Аминогетероарильные соединения в качестве ингибиторов протеинкиназ | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| DE602005012481D1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| EP1817312A4 (de) | Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer | |
| DK1730144T3 (da) | Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser | |
| SE0300457D0 (sv) | Novel compounds | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
| EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |